Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Res Social Adm Pharm ; 18(10): 3864-3866, 2022 10.
Article in English | MEDLINE | ID: mdl-35437231

ABSTRACT

BACKGROUND: Many facilities utilize outpatient parenteral intravenous (IV) antimicrobial therapy (OPAT) to reduce cost, length of stay, and risk of nosocomial infections. OBJECTIVE: The objective of this study was to analyze patient demographics, substance use, mental and physical health diagnoses, and social determinants of health to seek relationships with complications for veterans discharged from the Zablocki Veterans Affairs Medical Center (ZVAMC) on OPAT. METHODS: This study was a retrospective chart review of veterans who completed OPAT between the years of 2013 and 2017 at the ZVAMC in Milwaukee, Wisconsin. Prior to discharge, patients were screened by the OPAT team for eligibility; patients were followed after discharge by pharmacy, home care, and providers. OPAT complication was defined as antibiotic change/dose adjustment, IV catheter complication, or an additional hospital visit secondary to current infection or therapy. RESULTS: 294 veterans' charts were reviewed. Of these patients, 106 (36.05%) had a complication. Tobacco use was the only factor significantly associated with OPAT complication. CONCLUSIONS: Cohabitation, employment status, mental health diagnosis and alcohol use were not associated with OPAT failure; however, tobacco use merits further review for use in OPAT screening protocols.


Subject(s)
Anti-Bacterial Agents , Veterans , Ambulatory Care , Anti-Bacterial Agents/adverse effects , Humans , Infusions, Parenteral/adverse effects , Infusions, Parenteral/methods , Patient Discharge , Retrospective Studies
2.
Case Rep Hematol ; 2021: 3964465, 2021.
Article in English | MEDLINE | ID: mdl-34970462

ABSTRACT

Coccidioides is an endemic fungus in the Southwestern United States and Central and South America. Coccidioidomycosis primary infections are typically of the lung with an asymptomatic or self-limiting course. Some infections disseminate to other parts of the body and a few can remain latent for many years. Reactivation of latent fungal disease can occur following an insult to the host immune system. Here, we describe a case of a 76-year-old Caucasian male patient who moved from California to Wisconsin with a history of coccidioidomycosis infection of the left knee that reactivated decades later in his prosthetic knee shortly after being initiated on ibrutinib (Imbruvica), a Bruton tyrosine kinase (BTK) inhibitor, for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). There have been some case reports regarding coccidioidomycosis infections after initiating ibrutinib therapy but none with a 50 year latency period before reactivation. Readers will learn the immunological effects of ibrutinib on the hosts' innate and adaptive immunity and its role in putting the host at risk for invasive fungal infections. We also review the literature and data on treatment regimens and recommendations based on current guidelines.

4.
WMJ ; 118(4): 196-198, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31978290

ABSTRACT

INTRODUCTION: Francisella tularensis subspecies holarctica is the most common cause of tularemia in Europe and Japan. Tularemia presents in clinical syndromes, usually as ulceroglandular and glandular syndrome. This entity rarely causes endocarditis. In the United States, only 1 case of a native valve infectious endocarditis has been described to date. CASE PRESENTATION: In this article, we report a case of a patient with several weeks of fevers, night sweats, and myalgias who was diagnosed with prosthetic valve infectious endocarditis secondary to Francisella tularensis subspecies holarctica. DISCUSSION: Four previous case reports of Francisella tularensis endocarditis have been reported worldwide, with this being the first case of prosthetic valve endocarditis. Antibiotic therapy alone has provided effective treatment in all reported cases of endocarditis. CONCLUSION: Infective endocarditis caused by Francisella tularensis is an important entity for physicians to understand in areas of endemicity, especially in cases of culture-negative endocarditis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Heart Valve Prosthesis/microbiology , Tularemia/diagnosis , Tularemia/drug therapy , Diagnosis, Differential , Drug Therapy, Combination , Francisella tularensis , Humans , Male , Michigan , Middle Aged
5.
Case Rep Hematol ; 2016: 2389038, 2016.
Article in English | MEDLINE | ID: mdl-27843657

ABSTRACT

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of reactivation pulmonary tuberculosis in a retired physician while on treatment with ruxolitinib. We also review the literature on opportunistic infections following use of ruxolitinib. Our case highlights the importance of screening for latent tuberculosis in patients from highly endemic areas prior to start of therapy with ruxolitinib.

6.
World J Cardiol ; 2(5): 112-7, 2010 May 26.
Article in English | MEDLINE | ID: mdl-21160712

ABSTRACT

Renal dysfunction is common in patients with heart failure (HF) and can complicate HF therapy. Treating patients with HF and kidney disease is difficult and requires careful assessment, monitoring and balancing of risk between potential benefits of treatment and adverse impact on renal function. In this review, we address the pathophysiological contexts and management options in this adversarial relation between the heart and the kidney, which exists in a substantial proportion of HF patients. Angiotensin converting enzyme inhibitors and ß-blockers are associated with similar reductions in mortality in patients with and without renal insufficiency but usually are less often prescribed in patients with renal insufficiency. Careful monitoring of side effects and renal function should be done in all patients with renal insufficiency and prompt measures should be adopted to prevent further complications.

SELECTION OF CITATIONS
SEARCH DETAIL
...